Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide

@inproceedings{Kleinberg2012Polifeprosan23,
  title={Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide},
  author={Lawrence Kleinberg},
  booktitle={Core evidence},
  year={2012}
}
The Polifeprosan 20 with carmustine (BCNU, bis-chloroethylnitrosourea, Gliadel(®)) polymer implant wafer is a biodegradable compound containing 3.85% carmustine which slowly degrades to release carmustine and protects it from exposure to water with resultant hydrolysis until the time of release. The carmustine implant wafer was demonstrated to improve… CONTINUE READING